眼干燥症治疗药物的药效评价方法和产品研发进展  

Efficacy Evaluation Methods and Product Development Progress of Therapeutic Drugs for Ophthalmoxerosis

作　　者：孙子璇 陶涛[1] 赵雁[1] SUN Zixuan;TAO Tao;ZHAO Yan(National Pharmaceutical Engineering&Research Center,China State Institute of Pharmaceutical Industry,Shanghai 201203)

机构地区：[1]中国医药工业研究总院药物制剂国家工程研究中心,上海201203

出　　处：《中国医药工业杂志》2021年第12期1575-1583,共9页Chinese Journal of Pharmaceuticals

摘　　要：眼干燥症是常见的眼表疾病,轻中度眼干燥症已成为影响工作效率与生活质量的最常见眼表疾病之一,而重度眼干燥症会导致视力障碍。眼干燥症发病机制复杂且尚未完全明确,但已知炎症是该病发生发展的重要因素,临床亟需有效的治疗方法,尤其是在抗炎环节。本研究综述了眼干燥症药物治疗的研究进展,包括用于临床前研究的药效评价方法和动物病理模型,以及近年上市和正在进行临床研究的品种,以期为眼干燥症治疗药物的研发提供思路。Ophthalmoxerosis is a common ocular surface disease.Mild to moderate ophthalmoxerosis has become one of the most common ocular surface diseases that affects work efficiency and quality of life,while severe ophthalmoxerosis would lead to visual impairment.The pathogenesis of ophthalmoxerosis is complex and not yet fully understood,but inflammation is known to be an important factor in the occurrence and development of the disease.The effective therapeutic drugs are urgently needed in clinic,especially for anti-inflammatory treatment.This paper reviews the research progress of drug therapy for ophthalmoxerosis,including the efficacy evaluation methods and animal pathological models used in preclinical study,as well as the commercially available products on the market and candidates participating in clinical trials in recent years,so as to provide research ideas for the development of drugs for ophthalmoxerosis.

关 键 词：眼干燥症 发病机制 药效评价 动物模型 

分 类 号：R988.1[医药卫生—药品]